EYP-1901 vs Aflibercept for Diabetic Macular Edema

(DME Trial)

This trial tests two treatments, EYP-1901 and Aflibercept, to determine which is more effective for diabetic macular edema, a condition that causes vision problems due to diabetes. Researchers aim to discover if the experimental drug EYP-1901 is more effective than the established treatment, Aflibercept. Individuals with diabetic macular edema, whether previously treated or new to treatment, might be suitable candidates for this trial. Those who have received at least one anti-VEGF injection in the past year, but not in the last 12 weeks, may qualify. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify if you need to stop taking your current medications. However, if you have received anti-VEGF treatment for diabetic macular edema, it must have been at least 12 weeks before the screening visit.

Research has shown that EYP-1901 was safe in previous studies. In four completed trials, participants tolerated this treatment well, with no serious side effects linked to the drug. Researchers found no major safety issues, either in the eye or elsewhere in the body.

Aflibercept, another medication in this trial, has already received FDA approval for eye conditions. This approval confirms its safety for similar uses. Studies have shown it is generally well-tolerated, though, like any medication, it can have side effects, which are usually minor.

Unlike the standard treatments for diabetic macular edema, which typically involve repeated injections of medications like Aflibercept, EYP-1901 offers a unique approach. EYP-1901 is a sustained-release formulation, potentially reducing the need for frequent treatments. This new method targets the condition with a biodegradable delivery system, allowing for longer-lasting effects and potentially improving patient convenience and compliance. Researchers are excited about EYP-1901 because it could significantly enhance the quality of life for patients by decreasing treatment frequency while maintaining or improving efficacy.

This trial will compare EYP-1901 with Aflibercept for treating diabetic macular edema (DME). Research has shown that EYP-1901 may help treat DME. In earlier studies, 40% to 50% of patients who received EYP-1901 no longer had DME after 24 weeks. In contrast, none of the patients in the Aflibercept group were free of DME in the same study. Additionally, over 70% of those who received a single dose of EYP-1901 maintained stable vision for six months. These results suggest that EYP-1901 could be a promising option for managing DME.²⁴⁶⁷⁸